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Carcinoma: Adverse Effects Support the Trend toward 
Less Aggressive Treatment for Low-Risk Patients 
 E.N. Klein Hesselink    T.P. Links 
 Department of Endocrinology, University Medical Center Groningen, University of Groningen,  Groningen , The Netherlands 
 
function. THST can induce adverse cardiovascular effects in 
patients with DTC, such as diastolic and systolic dysfunction, 
and also adverse vascular and prothrombotic effects have 
been described. Finally, the effects of THST on bone forma-
tion and resorption are outlined; especially postmenopausal 
women with DTC on THST seem to be at risk of bone loss. In 
the past years, advances have been made in preventing low-
risk patients from being overtreated. Improved biomarkers 
are still needed to further optimize risk stratification and per-
sonalize medicine.  © 2015 European Thyroid Association
 Published by S. Karger AG, Basel 
 The incidence and prevalence of differentiated thyroid 
carcinoma (DTC) are steadily increasing. For example, 
the number of female DTC survivors in the USA was es-
timated to be 470,020 in 2014, and is expected to be 
645,330 in 2024  [1] . In particular the number of low-risk 
patients is increasing  [2] , for whom it is not clear wheth-
er treatment benefits outweigh the burden of therapy, and 
adverse effects could be prevented when overaggressive 
treatment is omitted.
 Over the past decades, standardized treatment has 
consisted of a total thyroidectomy accompanied by a cen-
tral or lateral neck lymph node dissection if indicated, 
 Key Words 
 Differentiated thyroid carcinoma · Radioiodine treatment ·
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 Abstract 
 Over the past decades, the incidence of differentiated thy-
roid carcinoma (DTC) has steadily increased, with especially 
a growing number of low-risk patients. Whereas DTC used to 
be treated rather aggressively, it is now acknowledged that 
aggressive treatment does not affect outcome for low-risk 
patients and that it can induce adverse effects. In this review 
an overview of the most clinically relevant adverse effects of 
radioiodine treatment and thyroid hormone suppression 
therapy (THST) is presented, and the trend toward less ag-
gressive treatment for low-risk patients is outlined. Salivary 
gland dysfunction occurs in roughly 30% of patients, and is 
probably due to the concentration of radioiodine in the sali-
vary glands by the sodium/iodide symporter. Beta radiation 
from radioiodine can result in sialoadenitis and eventually 
fibrosis and loss of salivary function. Furthermore, patients 
can experience bone marrow dysfunction following radioio-
dine treatment. Although this is in general subclinical and 
transient, patients that receive very high cumulative radioio-
dine doses may be at risk for more severe bone marrow dys-
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followed by radioiodine ( 131 I) ablation, and thyroid hor-
mone suppression therapy (THST) during follow-up. Al-
though treatment is tolerated well by most patients, ad-
verse effects of DTC treatment have been increasingly 
recognized  [3] , and were – and still are – reason for a de-
bate on the required aggressiveness of DTC treatment  [4] . 
Moreover, there is increasing doubt whether low-risk 
DTC patients benefit from radioiodine ablation and 
THST at all. The aim of the current review is to give an 
overview of the most clinically relevant adverse effects of 
radioiodine treatment and THST, and to discuss trends 
toward less aggressive treatment for patients with DTC.
 Radioiodine Therapy 
 Radioiodine therapy has been a mainstay for DTC 
treatment for decades. Due to the fairly specific uptake in 
thyroid cells, therapy is effective and relatively safe. In re-
cent years, the adverse effects of radioiodine treatment 
have been increasingly acknowledged, and treatment in-
dications critically reassessed. Focusing on the salivary 
glands and the bone marrow, we will discuss the main 
adverse effects of radioiodine therapy, and consider cur-
rent views on radioiodine treatment for low-risk patients 
in particular.
 Effects on Salivary Glands 
 Salivary glands have been estimated to concentrate io-
dine at 7 to 700 times the plasma level ( fig. 1 a, b)  [5] . This 
is probably linked to the presence of the sodium-iodide 
symporter (NIS) located in both thyroid follicular and 
salivary gland epithelial cells  [6, 7] . Saliva that is produced 
in the acini drains into intercalated ducts, after which stri-
ated ducts transport saliva to the excretory ducts. In hu-
man salivary glands, NIS is mainly expressed in the stri-
ated ducts, while acini do not contain NIS ( fig. 1 c)  [6] . By 
emitting beta radiation, radioiodine can cause an acute 
and/or chronic inflammatory reaction in the salivary 
gland parenchyma (sialoadenitis). As the ductal compart-
ment is particularly exposed to radiation, luminal debris 
and narrowing of the duct lumen may occur  [8, 9] . In ad-
dition to early toxicity, radioiodine can induce late effects 
( fig. 2 ). Damage to salivary gland stem cells, which have 
been proposed to mainly reside in the ductal compart-
ment and replenish progenitor, and eventually to ductal 
and acinar cells ( fig. 1 d)  [10] , can become apparent after 
one or several cell divisions, which take 60–120 days  [11] . 
Radiation injury can ultimately lead to fibrosis of salivary 
gland excretory tissue with loss of acini in particular, 
which can result in further decline of salivary gland func-
tion.
 Radioiodine-induced sialoadenitis can cause pain and 
swelling, reduced salivary flow (hyposalivation), the sen-
sation of oral dryness (xerostomia), and an increased risk 
of developing oral infections and dental caries  [12] . In a 
prospective study, 20 of 76 DTC patients (26%) devel-
oped complaints of pain, swelling or xerostomia either 
within 48 h or at least 3 months after radioiodine treat-
ment  [13] . The majority of patients still had complaints
1 year after ablation. An earlier report showed that 33% 
of DTC patients developed sialoadenitis within 3 months 
after ablation therapy, and 43% had complaints of de-
creased salivary gland function 1 year after the last radio-
iodine treatment  [14] . However, the reported frequency 
of salivary gland complaints varies widely  [5] , which may 
be due to the nonuniform method of xerostomia assess-
ment. Moreover, studies assessing hyposalivation by 
measuring parotid and submandibular saliva flow rates 
are, to the best of our knowledge, lacking for DTC pa-
tients.
 In general, parotid glands are affected more often than 
submandibular glands, and bilateral parotitis is more 
common than unilateral parotitis  [14–16] . This may be 
due to a higher saliva clearance rate in submandibular 
glands, which has been proposed to explain the higher 
NIS expression, but lower cumulative radioiodine activ-
ity found in submandibular versus parotid glands  [6] .
 In addition to patients with clinical overt sialoadenitis 
and xerostomia, many more patients have subclinical sal-
ivary gland dysfunction after radioiodine treatment. This 
was illustrated by a study of 79 patients in which both 
subjective (xerostomia complaints) and objective (tech-
netium-99m scintigraphy) signs of salivary gland dys-
function were studied  [15] . Salivary gland scintigraphy 
provides an objective assessment of salivary gland uptake 
and excretion function. However, it remains unclear 
which method is the gold standard for detection of radio-
iodine-induced salivary gland dysfunction. In the men-
tioned study, 33% had subjective and 51% had objective 
signs of salivary gland dysfunction during in the first year 
after radioiodine therapy. Moreover, 28 patients devel-
oped scintigraphic salivary gland dysfunction not earlier 
than in the third follow-up year, whereas only 2 had new-
onset xerostomia.
 Prevention and Treatment 
 The main recommendations to prevent salivary gland 
damage during radioiodine treatment include generous 
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 Fig. 1. Uptake of radioiodine in the parotid 
( a ) and submandibular glands ( b ) on the 
SPECT-CT scan, performed 7 days after ra-
dioiodine therapy.  c The NIS is mainly ex-
pressed in the striated ducts of salivary 
glands (S), and to a lesser extent in the in-
tercalated (rectangle) and excretory ducts 
(E). Acini (A) do not express NIS. Reprint-
ed with permission  [6] ,  © 2013 Mary Ann 
Liebert Inc.  d  Schematic representation of 
a salivary gland, with proposed locations of 
stem cells in excretory and striated ducts, 
and progenitor cells within the striated and 
intercalated ducts. The stem cell pool sup-
plies the progenitor cell pool, which in turn 
replenishes the population of duct and aci-
nar cells. Both stem and progenitor cells 
have the capacity to self-renew and differ-
entiate. Reprinted with permission [10] ,
 © 2013 Wiley. 
 Fig. 2. Proposed mechanisms of radioio-
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candy, vitamin C), and gland massage  [5] . However, 
whether or not to use sialogogues immediately after radio-
iodine treatment remains controversial, as there are con-
flicting results in the literature regarding this topic  [17–
20] . It was proposed that salivary gland blood flow and 
consequent radioiodine exposure was increased in pa-
tients who start using sialogogues within an hour after ra-
dioiodine ingestion  [17, 18] . Others, however, found a de-
creased rather than increased radioiodine absorbed dose 
in the parotid glands after early initiation of sialogogues 
 [19, 20] . The cholinergic pilocarpine was not found to de-
crease salivary gland damage following radioiodine treat-
ment in DTC patients  [21] . The effect may have been ob-
scured by high-dose dexamethasone, administered to all 
patients as an antiemetic. No beneficial effects were found 
for amifostine, a radical scavenger, either  [22] .
 Proposed treatment of radioiodine-induced sialoade-
nitis is mostly symptomatic with generous fluid intake 
and administration of gustatory or masticatory sialo-
gogues. Furthermore, anti-inflammatory drugs or refer-
ral to a dentist or oral surgeon may be useful  [5] . A new 
development within the field is the application of sialoen-
doscopy, which allows for the dilatation of duct stenoses, 
lavage of the ductal system and removal of mucus plugs. 
A subjective improvement in 23 of 30 patients after 
one treatment could be achieved using this technique 
 [16] . Furthermore, preparation for radioiodine treatment 
with recombinant human thyroid-stimulating hormone 
(rhTSH) instead of thyroid hormone withdrawal (THW) 
has been proposed to induce less salivary gland toxicity, 
as THW-induced hypothyroidism causes a transient im-
pairment of renal function, and therefore a slower renal 
clearance of radioiodine. In a prospective study of 148 
patients on rhTSH  [23] , 5.4 and 4.7% of patients had oral 
complaints 12 and 18 months postablation, respectively. 
This is lower than reported in the mentioned prospective 
studies with THW preparation for radioiodine therapy 
 [13, 15] . Studies cannot directly be compared though, as 
different questionnaires and definitions were used for sal-
ivary gland damage. Finally, a selective NIS blocker for 
salivary glands has been proposed  [6] , but as yet this is 
still a distant prospect.
 Effects on Bone Marrow 
 The bone marrow can be affected by radioiodine treat-
ment. This is probably due to radiation damage from pro-
tein-bound or free-circulating radioiodine  [24] , or a local 
effect in case of uptake of radioiodine in bone metastases.
 In most studies, a decrease in thrombocytes and leu-
cocytes (as a manifestation of bone marrow dysfunction) 
was found in a subset of patients  [24–27] . In a study per-
formed half a century ago in 159 thyroid carcinoma pa-
tients, 35% experienced anemia, 10% leucopenia and 3% 
had subnormal platelet counts after radioiodine treat-
ment  [25] . These cytopenias were subclinical in most cas-
es, and blood counts recovered within a year after the last 
radioiodine treatment. Data on the long-term effects of 
radioiodine of this study are unfortunately not reliable. 
Other studies had comparable results with regard to sub-
clinical toxicity and recovery of blood counts  [26, 27] , and 
additionally suggested higher toxicity with increasing cu-
mulative doses.
 Although the mentioned studies draw a reassuring 
picture with regard to bone marrow toxicity of radioio-
dine treatment, they were hampered by low patient num-
bers and a rather short follow-up. High-risk DTC pa-
tients with distant (bone) metastases may be at risk of 
bone marrow toxicity. These patients often receive high 
cumulative radioiodine doses that may result in high 
bone marrow radiation levels, and vital bone marrow 
may be replaced by tumor tissue, leading to impaired he-
matopoiesis. This is illustrated by a study of 107 DTC 
patients with initial bone metastases, treated with high-
dose radioiodine therapies  [28] . Four patients died from 
aplasia and 4 from acute myeloid leukemia after mean 
radioiodine doses of 70 and 87 GBq (1,892 and 2,351 
mCi), respectively.
 Prevention and Treatment 
 It has been suggested to use blood and bone marrow 
dosimetry studies to determine the radioiodine dose that 
can be safely administered  [29] , but this approach could 
not prevent blood count decreases in 50 thyroid carci-
noma patients who received a median dose of 606 mCi 
 [30] . Alternatively, preparation for radioiodine treatment 
with rhTSH instead of THW has been proposed to induce 
less bone marrow toxicity. rhTSH preparation is associ-
ated with a lower red marrow absorbed dose  [31] , and in 
a study performed in 15 elderly DTC patients no clini-
cally relevant bone marrow toxicity was observed after 
radioiodine therapy  [32] . However, no differences in pe-
ripheral blood counts were found between patients pre-
pared with THW and rhTSH in a larger-scale study  [33] . 
Stem cell preservation and, if indicated, a later bone mar-
row transplantation, has been proposed for those patients 
who are expected to receive high cumulative doses of ra-
dioiodine  [34] . Despite a case report on stem cell preser-
vation  [35] , there are no data available about whether and 
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 Radioiodine Treatment in Low-Risk DTC 
 Until the end of the 20th century, most DTC patients 
received high-dose radioiodine ablation therapy  [36] . 
Since then, the indication and appropriate dose for radio-
iodine therapy have been much debated. A multi-institu-
tional registry study and systematic literature analysis 
showed that radioiodine treatment was not associated with 
improved survival for low-risk patients  [4, 37] . Moreover, 
randomized controlled multicenter studies showed that 
low-dose radioiodine therapy of 1.1 GBq (30 mCi) was not 
inferior to a high dose of 3.7 GBq (100 mCi) with regard 
to short-term ablation success in DTC patients with a low 
 [38] and low-to-intermediate risk  [39] . In another pro-
spective randomized study of 309 low-risk DTC patients, 
the 5-year efficacy of ablation with 30, 60 and 100 mCi was 
compared  [40] . No difference in outcome at 5 years post-
ablation was found between the groups. However, 22% of 
patients ablated with 30 mCi needed another radioiodine 
therapy, whereas for patients initially treated with 60 or 
100 mCi, these numbers were 13 and 11%, respectively. 
The long-term efficacy of a low- versus high-dose radioio-
dine ablation therefore remains unclear, but a trend to-
ward lower radioiodine activities or even omission of abla-
tion in low-risk patients is clearly evident. A multicenter 
randomized trial that is currently recruiting low-risk DTC 
patients (NCT01398085) aims to study whether refraining 
from ablation is noninferior to low-dose ablation therapy 
with regard to the 5-year disease-free survival rate. This 
trial will finally give an answer to the question of whether 
or not radioiodine ablation is really needed in low-risk pa-
tients and, moreover, whether, in addition to short-term 
outcome, long-term outcome is noninferior.
 Thyroid Hormone Suppression Therapy 
 As with radioiodine treatment, a trend toward less ag-
gressive THST has occurred in the past 2 decades. Life-
long THST used to be recommended for all DTC patients 
 [36] , but in the current guidelines tapering of THST after 
the initial treatment or several years is recommended  [41, 
42] , especially for low-risk patients. As THST induces an 
iatrogenic (subclinical) hyperthyroid state, adverse ef-
fects on the cardiovascular system and bone density were 
expected on pathophysiological grounds, and could be 
confirmed in clinical studies.
 Cardiovascular Effects 
 Triiodothyronine is an important cardiovascular reg-
ulator. In myocytes it regulates transcription of multiple 
genes coding for proteins that influence cardiac function, 
and it affects several ion channels  [43] . By controlling in-
tracellular calcium and potassium concentrations, high 
triiodothyronine levels enhance cardiac contractility. 
Furthermore, triiodothyronine lowers systemic vascular 
resistance by acting on the vascular smooth muscle cells. 
Via the renin-angiotensin-aldosterone system, blood vol-
ume and therefore cardiac output increases, resulting in 
a hyperdynamic circulation  [44] . This can lead to cardiac 
hypertrophy, and could eventually cause systolic and dia-
stolic dysfunction. THST may induce elevated intracel-
lular triiodothyronine levels and consequently adverse 
cardiovascular effects, but this remains uncertain as it has 
been shown that circulating thyroid hormones do not 
necessarily reflect intracellular concentrations  [45] .
 The adverse cardiac effects of long-term THST were 
recognized about 2 decades ago. Diastolic dysfunction 
and an increased left ventricular mass and wall thickness 
were found in a heterogeneous group of DTC and multi-
nodular goiter patients on TSH-suppressive doses of
levothyroxine  [46] . The impaired diastolic function has 
been confirmed in DTC patients on THST for at least 10 
years  [47] . Importantly, in this study diastolic dysfunc-
tion reversed after a follow-up of 6 months in patients 
randomized to restore euthyroidism, while it remained in 
those randomized to stay on THST.
 Furthermore, THST can induce subtle ventricular dys-
function in DTC patients in the short-term, whereas more 
pronounced ventricular dysfunction may occur with long-
term therapy. Subtle ventricular dysfunction has been 
shown using 2D speckle tracking echocardiography  [48] , a 
relatively new technique that measures ventricular defor-
mation in the longitudinal, radial and circumferential 
plains ( fig.  3 ). Especially longitudinal myocardial strain 
has been shown to be of great value in detecting subclinical 
myocardial changes in cancer survivors, which can precede 
clinically relevant left ventricular ejection fraction (LVEF) 
decreases and heart failure  [49] . An impaired systolic func-
tion in terms of decreased longitudinal and circumferential 
strain was found in DTC patients on short-term THST as 
compared to controls  [48] . Radial strain, which is less sen-
sitive to hemodynamic stress or ischemia, was preserved 
along with the LVEF. However, for DTC patients on long-
term THST of the aforementioned study  [47] , a signifi-
cantly lower LVEF (although within the reference range) 
was found as compared to controls.
 Besides cardiac adverse effects, adverse vascular and 
prothrombotic effects of THST have also been described, 
albeit often in single studies. The arterial elasticity of both 
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 Fig. 3. 2D speckle tracking strain echocardiography measurements of longitudinal ( a ), radial ( b ) and circumfer-
ential strain ( c ). Left ventricular long- ( a ) and short-axis views ( b ,  c ) are shown on the left, with corresponding 
time-strain curves on the right. Arrows indicate the type of strain (deformation) measured. Strain measurements 
are performed in six myocardial segments (indicated with different colors) in each plane. The average strain of 
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long-term THST, as compared to controls  [50] . Further-
more, a prothrombotic state was found in 14 DTC patients 
on THST that resulted in a hyperthyroid state, as compared 
to the same population after THW-induced hypothyroid-
ism  [51] . Although the mechanisms of the mentioned car-
diovascular derangements are incompletely understood, 
they could add to the cardiovascular risk of DTC patients.
 DTC patients also have an increased risk of clinically 
overt cardiovascular disease. In a cross-sectional study of 
136 thyroid carcinoma patients on THST, prevalent atrial 
fibrillation (AF) was found in 10.3% whereas the predict-
ed prevalence would be 1–2% for the age- and sex-adjust-
ed general population  [52] . There was no difference in 
TSH between patients that did and those that did not have 
AF, although the reliability of the latter finding was lim-
ited as only one TSH level was used. In a recent larger-
scale retrospective study of low- and intermediate-risk 
DTC patients, no relation between the median TSH level 
during follow-up and AF was found either  [53] . In our 
center, a 3.3-fold increased risk of cardiovascular mortal-
ity was found in a cohort of 524 DTC patients, as com-
pared to 1,572 age- and sex-matched controls, indepen-
dent of cardiovascular risk factors  [54] . Moreover, an as-
sociation between lower TSH levels during follow-up and 
a higher risk of cardiovascular mortality was found within 
the DTC cohort, which remained after adjustment for car-
diovascular risk factors and DTC characteristics ( fig. 4 ).
 Prevention and Treatment 
 Although data on the prevention and treatment of 
THST-related cardiovascular adverse effects in DTC pa-
tients are lacking, a close follow-up with identification 
and treatment of cardiovascular risk factors and attention 
for rhythm disturbances seems justified.
 Effects on Bone Density 
 Both triiodothyronine and TSH have been reported to 
affect bone formation and resorption, although triiodo-
thyronine seems to be the major bone regulator, with a 
smaller fine-tuning role for TSH  [55] . Nuclear triiodothy-
ronine receptors (TRs) are widely expressed in bone. T3 
mainly acts on the TRα1 in bone, as unraveled from ex-
periments with TRα and TRβ mutant mice  [56] . During 
skeletal development, high T3 levels in loss-of-function 
TRβ mutant mice (with a defective pituitary feedback) in-
duced rapid bone formation and mineralization with pre-
mature closure of growth plates, whereas during adult-
hood elevated T3 resulted in accelerated bone remodeling 
with net bone loss  [56–58] . These TRβ mutant mice had 
skeletal hyperthyroidism, whereas in other experiments 
(loss-of-function) TRα mutant mice showed a phenotype 
of skeletal hypothyroidism, confirming the important role 
of TRα in bone metabolism. In addition to T3, TSH has 
been proposed to affect bone formation and resorption 
directly via TSH receptors on osteoblasts and osteoclasts 
a b
 Fig. 4. Kaplan-Meier curves of cardiovascular mortality in DTC 
patients versus controls ( a ), and cardiovascular mortality by TSH 
category ( b ), for patients with DTC. TSH category 1 represents a 
geometric mean TSH during follow-up below 0.02 mU/l; category 
2 represents a geometric mean TSH of 0.02–0.2 mU/l, and catego-
ry 3 represents a geometric mean TSH over 0.2 mU/l. Reprinted 
with permission  [54] ,  © 2013 American Society of Clinical Oncol-
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 [59] . TSH receptor knockout mice showed increased bone 
loss, even after administration of thyroid tissue extract 
that induced euthyroidism. As the latter was initiated at 
weaning, findings could also be due to severe hypothy-
roidism during the first weeks after birth, which is a criti-
cal phase for bone development  [55] . DTC patients on 
THST often have high-normal triiodothyronine levels 
 [60] and a low TSH; both can provide a rationale for ad-
verse effects of THST on bone mineral density (BMD).
 Postmenopausal women with DTC may suffer from 
bone loss  [53, 61–63] , while THST does not – or to a 
much lesser extent – affect BMD in premenopausal wom-
en and men  [64, 65] . Of female DTC patients randomized 
to THST (but not those randomized to a TSH in the nor-
mal range), patients of 50 years and older had a signifi-
cantly decreased BMD within 1 year, which was not ap-
plicable to those under 50 years of age  [61] . Furthermore, 
a 3.5-fold increased risk for developing osteoporosis was 
found for female DTC patients with a suppressed TSH as 
compared to patients with a nonsuppressed TSH, taking 
into account osteoporosis risk at baseline  [53] . After ad-
ditional adjustment for age, a 4.3-fold increased risk was 
found, indicating that THST is more harmful with in-
creasing age. More subtle bone loss may be assessed by 
peripheral quantitative computed tomography  [63] .
 In contrast, no adverse effects of THST in DTC pa-
tients were found at all in several cross-sectional studies 
that included postmenopausal women  [66–68] . In a co-
hort of 49 DTC patients and controls, no differences were 
found in BMD of the femur and lumbar spine  [67] . In 
another study, BMD Z-scores of DTC patients on long-
term THST were in the reference range  [68] . Discrepan-
cies in outcome could be due to differences in the degree 
and duration of THST, or inclusion or exclusion of pa-
tients with factors that can increase (postsurgical hypo-
parathyroidism  [69] , use of vitamin D, calcium or bisphos-
phonates) or decrease BMD (history of overt hyperthy-
roidism, estrogen or vitamin D deficiency).
 Prevention and Treatment 
 Oral calcium and bisphosphonates can prevent BMD 
losses in postmenopausal women with DTC, but seem re-
dundant in premenopausal women and men. A few stud-
ies showed promising data on this issue, but replication 
in larger studies is lacking, and prevention of BMD loss 
in postmenopausal DTC patients is not common prac-
tice. In one study, postmenopausal women with DTC 
randomized to receive oral calcium showed a stable BMD 
during a 2-year follow-up, whereas significant decreases 
were found in those randomized to placebo  [70] . In an-
other trial with mainly premenopausal women and men, 
patients were randomized to receive the parenteral 
bisphosphonate pamidronate and levothyroxine, or levo-
thyroxine and a placebo  [71] . DTC patients that received 
pamidronate showed significant increases in BMD dur-
ing the 2-year follow-up, whereas the placebo arm had a 
stable BMD over time.
 THST in Low-Risk Patients 
 Data on adverse effects of THST are accumulating, 
while there is an increasing uncertainty about the indica-
tion of THST for DTC patients, especially for those with 
a low risk of recurrence. Based on historical data and ex-
pert opinion  [36, 72, 73] , lifelong THST has been advo-
cated for all DTC patients for decades. However, in a lat-
er study it was shown that THST, as well as other treat-
ment modalities, did not affect survival outcomes for 
stage I patients  [4] . THST with TSHs in the subnormal 
and undetectable range did improve survival for stage II 
and stage III/IV DTC patients, respectively. Following the 
results of a unique Japanese study, it is advocated to use 
less aggressive treatment for papillary thyroid carcinoma 
patients as well  [74] . Such results are hard to compare 
with those obtained in the West though, since diagnostic 
and treatment approaches widely differ. Furthermore, in 
a recent study performed in low- and intermediate-risk 
DTC patients, TSH levels during follow-up did not affect 
the recurrence rate  [53] . An optimal TSH level of 0.9–1 
mU/l was proposed for patients with a low or intermedi-
ate risk, as with this level no increased risk for osteoporo-
sis was found, and a low risk of recurrence was main-
tained. With the latter studies in combination with an 
increased acknowledgement of the adverse effects of 
THST, a shift toward less aggressive THST has been 
made. For low-risk patients after initial treatment, a TSH 
in the low-normal range is advocated, while for high-risk 
patients a suppressed TSH during follow-up remains rec-
ommended for at least several years  [41, 42] .
 Conclusion 
 In this review, an overview of the most clinically rele-
vant adverse effects of THST and radioiodine treatment 
in DTC patients has been presented, and the shift toward 
less aggressive treatment for low-risk patients was out-
lined. For the growing category of low-risk patients with 
indolent tumors, aggressive treatment does not affect 
outcome, but it can induce adverse effects. In recent years, 
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from overtreatment. Better biomarkers are still needed to 
further personalize medicine and ensure adequate treat-
ment for those with a high risk, and spare low-risk pa-
tients from needless adverse effects.
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